Figures & data
Figure 1. a) A set of 12 omalizumab-naïve samples with various IgE levels was utilized for total and free IgE measurements using Genentech or the two commercial assays. Compared with the free IgE results obtained using the Genentech and ViraCor-IBT assays, 3 samples (#5, #52 and #56) under recovered significantly in the BioTeZ assay. (b) All 12 samples were omalizumabnaïve and therefore should not have measurable levels of omalizumab. However, the same 3 samples (#5, #52 and #56) yielded measurable false-positive levels of omalizumab in the BioTeZ omalizumab assay.
![Figure 1. a) A set of 12 omalizumab-naïve samples with various IgE levels was utilized for total and free IgE measurements using Genentech or the two commercial assays. Compared with the free IgE results obtained using the Genentech and ViraCor-IBT assays, 3 samples (#5, #52 and #56) under recovered significantly in the BioTeZ assay. (b) All 12 samples were omalizumabnaïve and therefore should not have measurable levels of omalizumab. However, the same 3 samples (#5, #52 and #56) yielded measurable false-positive levels of omalizumab in the BioTeZ omalizumab assay.](/cms/asset/a69cdb68-8cc3-4fa6-be59-7b0439505369/icmo_a_938150_f0001_b.jpg)